4//SEC Filing
Porter Derrell 4
Accession 0001209191-19-011175
CIK 0001604464other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 5:05 PM ET
Size
8.9 KB
Accession
0001209191-19-011175
Insider Transaction Report
Form 4
Porter Derrell
SVP, Head of Global Commercial
Transactions
- Exercise/Conversion
Common Stock
2019-02-15$14.30/sh+4,000$57,200→ 27,597 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-02-15−4,000→ 109,666 totalExercise: $14.30Exp: 2024-05-10→ Common Stock (4,000 underlying) - Sale
Common Stock
2019-02-15$40.00/sh−5,909$236,360→ 21,688 total
Footnotes (2)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018.
- [F2]25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001706400
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 5:05 PM ET
- Size
- 8.9 KB